In a groundbreaking move, the FDA has recently approved a device that enables individuals to screen for cervical cancer in the comfort of their own homes.

The Teal Wand, developed by Teal Health, is a prescription device that allows patients to self-collect samples, which are then mailed to a laboratory for testing, providing the same level of analysis as a doctor’s office.

Teal Health has secured a $10 million seed extension in January, increasing its total funding to $23 million, as reported by TechCrunch at the time. The investment round included notable participants such as Serena Ventures, Chelsea Clinton, Emerson Collective, and Forerunner. The device aims to address the intimidated feeling many people experience when it comes to getting screened for cervical cancer, also known as a pap smear.

According to Kara Egan, co-founder and CEO of Teal Health, “Cervical cancer screenings serve as a crucial entry point to a woman’s health relationship. Unfortunately, more than 1 in 4 women are currently overdue for this life-saving screening,” as stated in an interview with TechCrunch in January.

Historically, cervical cancer was one of the most common cancers affecting women, but increased screening and prevention efforts have contributed to a decline in its incidence, according to the American Cancer Society. The Wand Kit will comprise the collection device and virtual access to medical providers, who will review the lab results with the patient. The kits are scheduled to become available in June, starting with California.